parsaclisib + ibrutinib clinical trials

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

This study offers ongoing treatment for people with certain blood cancers (B-cell malignancies) who are already taking part in a different study with a drug called parsaclisib. It lets them continue their treatment if it's helping them.